• Low-Dose Decitabine Restores Immune Tolerance in ITP via Tre

  2026-05-20

  This study demonstrates that low-dose Decitabine (5-Aza-2'-deoxycytidine) can restore immune tolerance in immune thrombocytopenia (ITP) by selectively promoting regulatory T cell function and rebalancing helper T cell subsets. The findings provide mechanistic insight into Decitabine’s immunomodulatory effect, with implications for both hematopoietic malignancy research and the broader field of immune-mediated disorders.

• EPZ5676: DOT1L Inhibitor Workflows for MLL Leukemia Research

  2026-05-20

  EPZ5676, a potent DOT1L inhibitor, is transforming MLL-rearranged leukemia research with its exceptional selectivity and nanomolar efficacy. This guide details optimized workflows, troubleshooting strategies, and the latest insights on leveraging EPZ5676 for robust H3K79 methylation inhibition and acute leukemia cell line studies.

• Panobinostat (LBH589): Reliable HDAC Inhibition for Cell-Bas

  2026-05-19

  This article addresses how Panobinostat (LBH589) (SKU A8178) delivers reproducible, data-backed solutions to persistent challenges in cell viability and apoptosis assays. Scenario-driven Q&A blocks equip biomedical researchers with practical insights for optimizing epigenetic regulation studies and navigating vendor reliability—grounding all recommendations in recent evidence and product-specific performance.

• HyperScribe T7 High Yield RNA Synthesis Kit: Advanced In Vit

  2026-05-19

  Unlock robust, high-yield RNA synthesis for advanced molecular biology and functional genomics with the HyperScribe T7 High Yield RNA Synthesis Kit. Explore how this kit streamlines capped, biotinylated, and modified RNA production for applications ranging from oocyte maturation research to RNA vaccine development.

• M344: Potent Histone Deacetylase Inhibitor for Cancer Resear

  2026-05-18

  M344 is a potent, cell-permeable histone deacetylase inhibitor with nanomolar IC50, enabling precise modulation of gene expression. It effectively suppresses proliferation and induces differentiation in various cancer models, with specific efficacy shown in breast cancer, medulloblastoma, and neuroblastoma cells. M344 also enhances radiation response and has translational value in HIV latency research.

• I-BET-762 (SKU B1498): Data-Driven BET Inhibition in Cell As

  2026-05-18

  This article offers an evidence-based, scenario-driven guide to deploying I-BET-762 (SKU B1498) for high-fidelity cell viability, proliferation, and cytotoxicity experiments. By dissecting common laboratory challenges and providing real-world solutions, it highlights how this selective BET inhibitor enables reproducible, sensitive, and mechanistically validated workflows for cancer biology and inflammation research.

• Dual SMAD and Wnt Inhibition Enables Efficient iPSC-to-RGC D

  2026-05-17

  This study establishes a reproducible, chemically defined protocol for differentiating induced pluripotent stem cells (iPSCs) into highly pure retinal ganglion cells (RGCs) using dual SMAD and Wnt pathway inhibition. The methodology significantly reduces experimental variability and advances the field's capacity for modeling glaucoma and related neurodegenerative diseases.

• I-BET-762: BET Inhibitor Workflows for Ferroptosis & Inflamm

  2026-05-16

  I-BET-762 empowers translational research by selectively targeting BET proteins, enabling enhanced ferroptosis and anti-inflammatory effects across diverse models. This guide delivers experimental protocols, strategic troubleshooting, and actionable insights rooted in recent mechanistic advances.

• Valemetostat (DS-3201): Epigenetic Modulation to Boost Immun

  2026-05-15

  Explore how Valemetostat (DS-3201) uniquely enhances adoptive T cell immunotherapy through dual EZH1/EZH2 inhibition. This in-depth analysis reveals new mechanistic insights and practical assay guidance for lymphoma research.

• SIRT1/2 Inhibitor IV (cambinol): Applied Protocols & CNS Ins

  2026-05-15

  SIRT1/2 Inhibitor IV (cambinol) enables researchers to dissect metabolic-epigenetic crosstalk in both cancer and CNS injury models with unmatched specificity. Its unique ability to modulate non-histone lactylation, such as Ran K123, empowers high-impact applications from tumor suppression to astrocyte polarization studies.

• SP2509: Potent Lysine-Specific Demethylase 1 Antagonist for

  2026-05-14

  SP2509 is a highly potent lysine-specific demethylase 1 antagonist that selectively inhibits LSD1, driving apoptosis and differentiation in acute myeloid leukemia (AML) models. It offers a targeted approach to epigenetic modulation without affecting monoamine oxidases, making it a valuable tool for cancer epigenetics research.

• Oxaliplatin in Preclinical Oncology: Mechanisms and Synergis

  2026-05-14

  Explore the advanced mechanisms of Oxaliplatin, a platinum-based chemotherapeutic agent, with a focus on its synergy with novel sensitizers and its expanding utility in cancer biology research. Gain practical insights for optimizing assay design and translational applications.

• Sulfamonomethoxine (SKU BA1078): Reliable Solutions for Lab

  2026-05-13

  This article provides a scenario-driven, evidence-based guide for using Sulfamonomethoxine (SKU BA1078) in cell viability and environmental toxicity assays. It addresses real laboratory challenges, supports protocol optimization, and compares vendor reliability—empowering researchers to achieve reproducible and sensitive results with confidence.

• Toremifene Citrate: Mechanism, Efficacy, and Clinical Parame

  2026-05-13

  The reference study elucidates Toremifene Citrate’s dual estrogen receptor modulatory activity and documents its clinical equivalence to tamoxifen for postmenopausal women with advanced breast cancer. Key insights include its pharmacokinetics, safety profile, and implications for hormone receptor-positive tumor management.

• BRD4 Inhibitors Enhance Erastin-Induced Ferroptosis via ROS

  2026-05-12

  This study demonstrates that BRD4 inhibition, including with I-BET-762, broadly sensitizes diverse cancer cell lines to erastin-induced ferroptosis by increasing reactive oxygen species (ROS) and downregulating FSP1. The findings clarify mechanistic links between BET inhibition and ferroptosis, informing translational strategies in cancer biology and drug resistance.

16716 records 3/1115 page Previous Next 12345 下5页 Last page